Mission 1
We're establishing health security by securing vaccine and treatment sovereignty through timely R&D support.
This allows us to respond to government-wide and societal threats like infectious diseases and biochemical terrorism.
STOREx : Stockpile Technology to Omit Repeated Entityfor Vx
Goal
Extending vaccine shelf life from 3 years to over 10 years to improve stockpiling methods and activate proactive vaccine stockpiling → Development of long-term vaccine preservation technology.
- Development of vaccine technology enabling single production and long-term stockpiling for over 10 years.
- Technology that enables proactive vaccine development and expansion of stockpiled vaccines.
Problem
Limited shelf life and uncertain timing of use make it difficult to establish effective stockpiling strategies.
- Wasteful budget execution due to repeated production and disposal.
- Shelf life acts as a barrier to proactive vaccine development and stockpiling strategies.
Innovation
Ultra-long-term shelf life extension through application of convergent technologies.
- Combination of chemical degradation prevention and enhanced physical stability.
Utilization
Strengthening pandemic preparedness through expansion of vaccine stockpile types.
- Improved budget efficiency through extended shelf life.
- Activation of vaccine stockpiling strategies and expansion of response coverage.
-
Enhanced long-term storage stability based on MAPS technology.
-
Increased shelf life through inhibition of hydrolysis.
PM Introduction
Hong, Kee Jong PM View Profile
Strengthening Health Security through Vaccine and Treatment Sovereignty
- 02-2288-6140
- calcium2@khidi.or.kr
DeCAFx : DeCentralizing & Accelerating Facility for Vx
Goal
Integrated, Small-Scale, Mobile Vaccine Production Module Prototype Development → Rapid Vaccine Production Module Development
- Develop a modular production system capable of rapidly producing 1 million doses within 100 days.
- Develop a flexible modular production design that allows for on-site production in needed areas within 30 days.
Problem
Absence of Localized Production Systems for Rapid Vaccine Development/Supply During Pandemics
- Rapid pandemic response requires localization of production processes by country.
- Necessary to close regional gaps in vaccine technology and overcome disparities in supply prioritization.
Innovation
Ensuring Rapid and Flexible Vaccine Production Through the Development of an mRNA Technology-Based Mobile/Fully Integrated Production Facility
- Integrate the entire process, from antigen design to mRNA antigen production and final vaccine product
Utilization
Securing International Competitiveness and Establishing Customized Cancer Treatment Production Services
- Develop products that can compete with those from leading international companies.
- Establish on-site production technology or services for personalized, small-scale development/production of anti-cancer treatment vaccines.
-
Build an integrated, full-cycle process for rapid production based on mRNA vaccine technology.
-
Manufacture small-scale mobile production modules.
PM Introduction
Hong, Kee Jong PM View Profile
Strengthening Health Security through Vaccine and Treatment Sovereignty
- 02-2288-6140
- calcium2@khidi.or.kr